ClinicalTrials.gg
Status unknownNCT01393080NSCLCUpdated Feb 17, 2016

Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients

An interventional study of Nimotuzumab and TP regimen and TP regimen in Non-small Cell Lung Cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-02-17.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Feb 2013), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing nimotuzumab in Carcinoma, Non-Small-Cell Lung — none open to participants now, none under way, none of them phase 3. nimotuzumab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
2nd of 10
160 · median 87
Started
2011
with 2 others
No phase
2 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
1 of 10
Tianjin Medical University Cancer Institute and Hospital

Among the 10 studies testing nimotuzumab in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2011, is one of 2 with no phase, and was the 5th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

None of the 10 studies testing nimotuzumab in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →

About nimotuzumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing nimotuzumab in Carcinoma, Non-Small-Cell Lung as a file.
02

Study summary

Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adults with head and neck cancer. This study assesses the efficacy and safety of the combination of Nimotuzumab administered concomitantly with chemotherapy in patients with NSCLC. This is a randomized, muti-center sites trial of this treatment.

Read the detailed description

This is a randomized, muti-center sites trial of Nimotuzumab combination with Paclitaxel Liposome and Carboplatin (TP regimen) treatment.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • nimotuzumab
  • non-small cell lung cancer
  • chemotherapy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signature of the form
  2. Ages from 18 to 70 years old; both male and female.
  3. Pathologically and/or cytologically ① the patients of ⅢB~Ⅳstage NSCLC; ② the patients of IIIA stage NSCLC could not receive the operation or could not operate. ③ the patients of IIIA stage NSCLC are recurrent postoperation.
  4. EGFR mRNA from peripheral bloods is positive by ELISA or the expression of EGFR from tumor tissue is positive by immunohistochemical staining.
  5. Functions of major organs( haemogram,heart,liver,kidney)are basically normal, White blood count ≥3.5 x 109/L with neutrophils ≥1.5 x 109/L, count≥100 x 109/L, and ≥90g/L.

    Total ≤1.5 times (ULN) range; alkaline phosphatase(ALP)≤ 2.5 times ULN, Transaminases (SGOT) and ALT (SGPT) ≤ 2.5 times ULN, serum creatinine ≤ 1.2 times ULN .

  6. With performance status 0-2;
  7. Both female and male patients must use adequate methods of .

Exclusion criteria

Exclusion Criteria:

  1. Participation other clinical trials within 1 month prior to inclusion in the trial.
  2. Previous targeted treatment of TKI or EGFR antibodies prior to inclusion in the trial.
  3. Previous paclitaxel liposome and carboplatin (TP) chemotherapy prior to inclusion in the trial.
  4. With other serious internal diseases or uncontrolled infection;refractoriness dysentery or enterospasm, intestinal obstruction.
  5. Cardiovascular diseases history (1)Uncontrollable hypertension, unstable angina, heart infarction, or congestive heart failure and arrhythmia ( happened within 12 month prior to inclusion in the trial) (2)Ischemia checked by , or clinical diagnostic Heart valve disease (3)The patients of Grade II(CTC AE 3.0) of arrhythmia, myocardial ischemia, troponin T abnormality, hypertension or \<50%,could not include in the TP+ nimotuzumab test group;
  6. With drug addition, I.e. ,drug-taking, drug-taking for long time; type B hepatitis and C hepatitis in active stage, or with AIDS.
  7. Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ, curative carcinoma of prostate.
  8. With history of serious allergic or allergy.
  9. Patients with less compliance
  10. Pregnancy, lactation, fertility but using a prohibited method.
  11. Not fit for the clinical trial judged by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Nimotuzumab and TP regimen

    1. TP Regimen :Paclitaxel Liposome,135mg/m2,d1;Carbopatin(AUC=5) d2, 3 weeks/cycle, for 4 cycles. 2. Nimotuzumab : 200mg/w, weekly, for 6 weeks; Consolidation treatment, 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression.

    Drug: Nimotuzumab and TP regimen

  • Placebo comparator
    TP Regimen

    TP Regimen:Paclitaxel Liposome,135mg/m2,d1;Carbopatin(AUC=5) d2, 3 weeks/cycle, for 4 cycles.

    Drug: TP regimen

Interventions

  • DrugNimotuzumab and TP regimen

    Drug pages: NimotuzumabStudies of NimotuzumabNimotuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TP protocolStudies of TP protocolTP protocol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1. TP Regims:Paclitaxel Liposome,135mg/m2,d1;Carbopatin(AUC=5) d2, 3 weeks/cycle, for 4 cycles. 2. Nimotuzumab: 200mg/w, weekly, for 6 weeks; Consolidation treatment, 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression.

  • DrugTP regimen

    TP Regimen:Paclitaxel Liposome,135mg/m2,d1;Carbopatin(AUC=5) d2, 3 weeks/cycle,for 4 cycles.

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    Time frame: 12months

Secondary outcomes

  1. Overall survival Time

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
  • Tianjian Medical University Cancer Institue and Hospital
    Tianjin, Tianjin, China
    Recruiting
    • Daliang Qi, MD · Contactxj2880@gmail.com · +862223340123
    • Daliang Qi, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2011
First posted
Jul 13, 2011
Start
Mar 2011
Primary completionEst.
Dec 2016
CompletionEst.
Dec 2016
Last update
Feb 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01393080
Collaborators
Biotech Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jul 13, 2011
Start date
Mar 2011
Primary completion
Dec 2016 (estimated)
Completion
Dec 2016 (estimated)
Last update
Feb 17, 2016

Study contacts

Daliang Qi, MD
Contact
xj2880@gmail.com
0086-22-23340123 ext. 3502
Jie Xu, MD
Contact
xj2880@tom.com
0086-22-23340123 ext. 3503
Daliang Qi, Master
principal investigator · Tianjin Medical University Cancer Institute and Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nimotuzumab · TP protocol

Start the discussion